Compare NUCL & CDXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NUCL | CDXS |
|---|---|---|
| Founded | 2023 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Metals and Minerals | Major Chemicals |
| Sector | Basic Materials | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 308.2M | 256.3M |
| IPO Year | N/A | 2008 |
| Metric | NUCL | CDXS |
|---|---|---|
| Price | $7.87 | $2.66 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 463.7K | ★ 863.4K |
| Earning Date | 05-22-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 43.82 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $138,590,000.00 |
| Revenue This Year | N/A | $7.73 |
| Revenue Next Year | N/A | $14.24 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 32.30 |
| 52 Week Low | $4.63 | $0.96 |
| 52 Week High | $14.22 | $3.87 |
| Indicator | NUCL | CDXS |
|---|---|---|
| Relative Strength Index (RSI) | 34.45 | 59.00 |
| Support Level | $4.63 | $2.41 |
| Resistance Level | $12.23 | $2.73 |
| Average True Range (ATR) | 0.93 | 0.16 |
| MACD | -0.18 | 0.02 |
| Stochastic Oscillator | 1.36 | 97.12 |
Eagle Nuclear Energy Corp is a next-generation nuclear energy company that seeks to combine domestic uranium exploration and development with proprietary small modular reactor (SMR) technology. It holds the rights to the mineable, measured and indicated uranium deposit in the United States, referred to as the Aurora Uranium Project, located in southeastern Oregon. The Aurora Uranium Project includes the Aurora deposit, with an estimated 37.73 million pounds of near-surface uranium and the adjacent Cordex Zone Eagle's SMR technology. Eagle's mission is to supply uranium to the growing nuclear energy industry and play a role in the global transition to clean, reliable, and affordable energy.
Codexis Inc is a biotechnology company engaged in providing enzyme-based technology solutions to improve pharmaceutical manufacturing processes. The company operates through two key business areas: the ECO Synthesis manufacturing platform and small molecule pharma biocatalysis. The ECO Synthesis platform focuses on developing enzymatic processes for the large-scale manufacture of RNA interference therapeutics, while the biocatalysis business utilizes engineered enzymes to enhance efficiency, yield, and sustainability in small molecule drug manufacturing. Geographically, it derives maximum revenue from the Americas.